LH SEC Filings

Labcorp Holdings 8-K Report, Regulation FD Disclosure (Nov 4, 2026)

Labcorp Holdings Quarterly Report for Q3 Ended Sep 30, 2026

Labcorp Holdings Inc. reported third-quarter 2026 revenues of $3.81 billion, up 6.9% from $3.56 billion a year earlier, with organic revenue growth of 5.5% and acquisitions contributing 1.5%. Operating income rose 1.4% to $402.1 million, and net earnings attributable to Labcorp Holdings Inc. were $262.8 million, or $3.22 per diluted share, compared with $261.1 million, or $3.12 per diluted share, a year earlier. Nine-month revenues were $11.08 billion, up 6.2%, with net earnings attributable to the company of $839.3 million, or $10.22 per diluted share, versus $8.48 per diluted share in the prior-year period. Segment operating margins expanded in both Diagnostics Laboratories and Biopharma Laboratory Services, though general corporate and unallocated expenses rose to $153.9 million for the quarter from $110.6 million, citing higher LaunchPad costs and acquisition and disposition-related costs. Cash generation and capital deployment were significant over the nine months. Net cash provided by operating activities was $1.20 billion, up from $1.03 billion, while the company spent $404.2 million on capital expenditures and $683.4 million on business acquisitions, net of cash acquired. The company repurchased $451.8 million of common stock, paid $178.1 million in dividends, and took out a $750.0 million 2026 Term Loan due 2028. Cash and cash equivalents fell to $261.8 million at September 30, 2026, while the board authorized an additional $1.00 billion of repurchases on July 8, 2026, leaving $1,378.6 million available. Total debt-related commitments and the company's own acquisition pipeline also stand out, including agreements announced in October 2026 to acquire assets of BioReference Health's laboratory business for up to $872.0 million, Myriad Genetics' Prenatal Health testing business for approximately $210.0 million plus inventory, and Millennium Health for up to $375.0 million. The filing reports that the company was in compliance with its debt covenants at September 30, 2026. Management stated it believes it has sufficient liquidity for the next 12 months, and it expects to refinance its $600.0 million 3.60% senior notes due September 1, 2027, at likely higher interest rates. Legal matters include the AMCA data security class action, which received final court approval on August 20, 2026, and the Ravgen patent case, with oral argument before the Federal Circuit scheduled for December 15, 2026.

Labcorp Holdings 8-K Report, Financial Results (Oct 28, 2026)

Labcorp Holdings Inc. reported third-quarter 2026 results for the period ended September 30, 2026, with revenue of $3.81 billion, up 6.9% from $3.56 billion, and adjusted EPS of $4.78, up 14.5% from $4.18. Diluted EPS was $3.22, up 3.3% from $3.12. Organic revenue growth was 5.5%, and acquisitions contributed 1.5%. Operating income was $402.1 million, or 10.6% of revenue, compared with 11.1% a year earlier, while adjusted operating income rose to $570.0 million, or 15.0% of revenue, from 14.4%. Free cash flow was $412.2 million, up from $280.5 million. The company raised its full-year 2026 guidance. Enterprise revenue growth is now projected at 5.9% to 6.7%, up 50 basis points at the midpoint, and adjusted EPS is projected at $18.30 to $18.70, up 18 cents at the midpoint. Free cash flow guidance of $1,240 million to $1,360 million was unchanged. Guidance includes the estimated impact of planned acquisitions, share repurchases, and dividends. Biopharma Laboratory Services guidance was raised most significantly, to $3,328 million to $3,358 million in revenue, with growth of 7.4% to 8.4%. Management highlighted an active M&A agenda. Four transactions were announced or closed during the quarter, including the acquisition of MLM Medical Labs, and three further acquisition agreements were signed after quarter end: select assets of BioReference Health's laboratory testing businesses, Myriad Genetics' Prenatal Health testing business, and Millennium Health. Each is subject to regulatory approval and customary closing conditions. The company also declared a quarterly dividend of $0.72 per share, payable December 11, 2026, and reported $1.4 billion remaining under its share repurchase authorization. Total debt was $5.85 billion and cash was $261.8 million at quarter end.

Labcorp Holdings 8-K Report, Regulation FD Disclosure (Oct 21, 2026)

Labcorp Holdings Inc. (NYSE: LH) filed a Current Report on Form 8-K dated October 21, 2026, under Item 7.01 (Regulation FD Disclosure) to announce that its Board of Directors has declared a quarterly cash dividend of $0.72 per share of common stock. The dividend is payable on December 11, 2026, to stockholders of record as of the close of business on November 24, 2026. The accompanying press release, furnished as Exhibit 99.1, is titled "Labcorp Declares Quarterly Dividend" and is incorporated by reference into the filing. The filing contains no financial results, guidance, or other operational disclosures. Its substance is limited to the dividend declaration, with the press release also describing Labcorp as a global laboratory services provider with nearly 71,000 employees serving clients in approximately 100 countries.

Labcorp Holdings 8-K Report, Regulation FD Disclosure (Sep 30, 2026)

Labcorp Holdings Inc. (NYSE: LH) furnished a Form 8-K under Item 7.01 (Regulation FD Disclosure) on September 30, 2026, announcing that it will release its third-quarter 2026 financial results before the market opens on Wednesday, October 28, 2026. The company will host a webcast beginning at 9:00 a.m. ET that day to discuss the results. The filing's accompanying press release (Exhibit 99.1), dated September 30, 2026, serves as the scheduling announcement. It states that the earnings press release and accompanying financial information will be posted on the "News & Events" section of the Labcorp Investor Relations website, where a webcast link will also be available. A webcast replay is to be available about two hours after the live event and for one year. The filing contains no financial results, guidance, or other performance metrics. Its investor relevance is limited to the timing and access details for the third-quarter 2026 earnings release and call.

Labcorp Holdings 8-K Report, Regulation FD Disclosure (Sep 22, 2026)

On September 21, 2026, the Centers for Medicare & Medicaid Services (CMS) released preliminary Clinical Laboratory Fee Schedule payment rates for 2027 through 2029 under the Protecting Access to Medicare Act (PAMA). Labcorp Holdings Inc. states that the rates are based on data not fully representative of the broader commercial laboratory market and would impose steep annual payment cuts that threaten patient access to laboratory services. The company says it continues to support the bipartisan RESULTS Act, which it describes as a solution to ensure a sustainable and innovative U.S. laboratory system. The company states it had already considered the anticipated continuation of PAMA-related reimbursement pressure when it set its 2026-2029 long-term outlook at its September 10, 2026 Investor Day, and it is reaffirming that outlook. The reaffirmed targets are compound annual revenue growth of 5% to 8%, adjusted operating margin expansion of 75 to 150 basis points by the end of 2029, compound annual adjusted EPS growth of 8.5% to 11.5%, and compound annual free cash flow growth in line with adjusted earnings growth. Labcorp is still evaluating the CMS payment rates and says it expects to disclose the impact on its 2027 financial guidance when that guidance is announced in February 2027. Investors should note that the outlook is presented as a forward-looking, non-GAAP-based projection, and the company does not provide forward-looking reconciliations of its adjusted measures.

Labcorp Holdings 8-K Report, Regulation FD Disclosure (Sep 10, 2026)

On September 10, 2026, Labcorp Holdings Inc. (NYSE: LH) hosted its 2026 Investor Day, providing an in-depth review of its growth strategy, innovation roadmap, and long-term financial outlook. The company reaffirmed its full-year 2026 guidance, which was last updated on July 30, 2026, calling for Labcorp Enterprise revenue of $14.71 billion to $14.83 billion, adjusted EPS of $18.10 to $18.55, and free cash flow of $1.24 billion to $1.36 billion. For the longer term, Labcorp outlined expectations through 2029 of compound annual revenue growth of 5% to 8%, adjusted operating margin expansion of 75 to 150 basis points by the end of 2029, compound annual adjusted EPS growth of 8.5% to 11.5%, and free cash flow growth in line with adjusted earnings growth. Management described four strategic priorities: specialty testing (oncology, neurology, autoimmune diseases and women's health), partnerships with health systems and pharmaceutical companies, personalized health solutions, and technology including AI and robotics. The outlook assumes foreign exchange rates as of June 30, 2026 and incorporates potential return of PAMA. The Investor Day materials, furnished as Exhibits 99.1 and 99.2, also present a capital deployment framework for 2027 to 2029 that includes operating cash flow of $6.3 billion to $7.2 billion, capital expenditures of approximately 4% of revenue, dividends targeted at 15% to 20% of adjusted earnings, and M&A contributing 1.5% to 2.5% revenue CAGR. The information is furnished under Item 7.01 and is not deemed filed under Section 18 of the Exchange Act.

Labcorp Holdings 8-K Report, Regulation FD Disclosure (Aug 28, 2026)

Labcorp Holdings Inc. (NYSE: LH) furnished a Form 8-K under Item 7.01 (Regulation FD Disclosure) on August 28, 2026, announcing that members of its executive management team will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026, at 11:30 a.m. ET. The filing is an informational notice rather than a financial or operational disclosure, and it contains no financial results, guidance, or new material business developments. A live audio webcast of the fireside chat will be available through the Labcorp Investor Relations website at ir.labcorp.com, and the webcast will be archived for replay for 180 days following the event. The accompanying press release (Exhibit 99.1), dated August 28, 2026, is furnished and incorporated by reference, and it describes Labcorp as a global leader of innovative and comprehensive laboratory services. The boilerplate in the press release states that Labcorp has nearly 71,000 employees, serves clients in approximately 100 countries, supported more than 85% of the new drugs and therapeutic products approved by the FDA in 2025, and performed more than 750 million tests for patients worldwide. For investors, the filing's primary relevance is the opportunity to hear management commentary at the conference and to access the replay.

Labcorp Holdings 8-K Report, Regulation FD Disclosure (Aug 17, 2026)

On August 17, 2026, Labcorp Holdings Inc. (NYSE: LH) announced it will host an Investor Day on Thursday, September 10, 2026, from 9 a.m. to noon ET. The filing is a Regulation FD disclosure under Item 7.01, furnishing a press release as Exhibit 99.1 that announces the event. According to the filing, Chairman and CEO Adam Schechter, Executive Vice President and CFO Julia Wang, and other members of the executive leadership team will discuss the company's go-forward strategy, capital deployment priorities and long-term financial outlook. Presentations will be followed by a question-and-answer session. A live webcast will be available through the Labcorp Investor Relations website beginning at 9 a.m. ET, with a replay and supporting materials to be posted after the event concludes. The filing contains no financial results or quantitative guidance; its investor relevance lies in management's planned discussion of long-term strategy, capital allocation and financial outlook.

Labcorp Holdings 8-K Report, Executive Changes (Aug 14, 2026)

Labcorp Holdings Inc. (LH) filed this Current Report on Form 8-K under Item 5.02, disclosing executive leadership changes. Megan D. Bailey notified the Company on August 11, 2026 of her decision to resign as Executive Vice President and President, Central Laboratories and International, effective September 4, 2026. Effective September 1, 2026, Brian J. Caveney, M.D., currently Executive Vice President and President, Early Development Research Laboratories and Chief Medical and Scientific Officer, will assume the role of Executive Vice President and President, Biopharma Laboratory Services and Chief Medical and Scientific Officer. In this expanded role he will be responsible for the Company's Early Development Research Laboratories and Central Laboratories businesses. The filing does not disclose any financial results, compensation terms, or reasons for Ms. Bailey's departure. For investors, the key takeaway is a consolidation of the Central Laboratories and Early Development Research Laboratories businesses under a single executive, effective September 2026.

Labcorp Holdings Quarterly Report for Q2 Ended Jun 30, 2026

Labcorp Holdings Inc. (LH) reported revenues of $3,731.1 million for the three months ended June 30, 2026, up from $3,527.3 million a year earlier, and $7,268.7 million for the six months, up from $6,872.4 million. The quarter's revenue increase of 5.8% was attributed to organic revenue of 4.2%, acquisitions net of divestitures of 1.2%, and favorable foreign currency translation of 0.4%. Operating income rose to $451.6 million from $394.5 million, and net earnings attributable to Labcorp Holdings Inc. were $298.7 million, or $3.64 per diluted share, versus $2.84 a year earlier. Dx and BLS contributed approximately 78% and 22% of revenues, respectively. Cash flow and capital allocation were central to the period. Net cash provided by operating activities was $637.0 million for the six months, roughly flat with $639.1 million a year earlier. The company acquired businesses for $427.9 million net of cash acquired, spent $252.6 million on capital expenditures, and repurchased $451.8 million of common stock. Cash and cash equivalents fell to $141.8 million at June 30, 2026, while long-term debt increased to $5,857.6 million, reflecting a new $750.0 million 2026 Term Loan used to redeem the 1.55% senior notes due 2026. After the period end, the Board authorized an additional $1,000.0 million repurchase, bringing total authorization to $1,378.6 million, and declared a $0.72 per share dividend payable September 11, 2026. The filing also reports that the Texas Supreme Court reinstated a District Court judgment in the company's favor in the Texas Medicaid qui tam matter on June 19, 2026, and that the company settled a DOJ urine drug testing subpoena on July 15, 2026. The Ravgen patent judgment remains under appeal, and the AMCA-related class action is subject to court approval of a settlement.

Labcorp Holdings 8-K Report, Financial Results (Jul 30, 2026)

Labcorp Holdings Inc. (NYSE: LH) furnished an 8-K on July 30, 2026, under Item 2.02 (Results of Operations and Financial Condition), attaching a press release announcing its second quarter 2026 results and raising its full-year 2026 guidance. Second-quarter revenue was $3.73 billion versus $3.53 billion a year earlier, up 5.8%. Diluted EPS was $3.64 versus $2.84, and adjusted EPS was $4.99 versus $4.35, up 14.9%. Operating income was $451.6 million, and adjusted operating income was $588.7 million, or 15.8% of revenue versus 15.1% a year earlier. Free cash flow for the quarter was $313.9 million, compared with $542.7 million a year earlier, which the company attributed primarily to working capital timing and planned increases in capital expenditures. The company raised its 2026 enterprise revenue guidance to $14,710 million to $14,827 million (5.4% to 6.3% growth) and its adjusted EPS guidance to $18.10 to $18.55, up 30 cents at the midpoint. Free cash flow guidance was unchanged at $1,240 million to $1,360 million. Segment results were mixed in detail: Diagnostics Laboratories revenue rose 5.5% with adjusted operating margin of 18.0%, while Biopharma Laboratory Services revenue rose 6.5% with adjusted operating margin of 17.0%. Capital allocation was active during the quarter. Labcorp invested $225.7 million in acquisitions, repurchased $353.8 million of stock, paid $58.7 million in dividends, and retired $500.0 million of senior notes in June. In July the Board approved a $1.0 billion increase in the share repurchase authorization, bringing the remaining total to $1.4 billion. Total debt at quarter-end was $5.86 billion against cash of $141.8 million.

Labcorp Holdings 8-K Report, Regulation FD Disclosure (Jul 10, 2026)

Labcorp Holdings Inc. (NYSE: LH) furnished a Form 8-K under Item 7.01 (Regulation FD Disclosure) reporting that its Board of Directors declared a cash dividend of $0.72 per share of common stock. The announcement was made on July 9, 2026, and the filing was dated July 10, 2026. The dividend is payable on September 11, 2026, to stockholders of record as of the close of business on August 28, 2026. The accompanying press release, furnished as Exhibit 99.1, is titled "Labcorp Declares Quarterly Dividend" and is incorporated by reference into the filing. The filing is a routine capital-return notice and contains no financial results, guidance, or other operating information. The press release describes Labcorp as a global laboratory services company with nearly 71,000 employees serving clients in approximately 100 countries.

Labcorp Holdings 8-K Report, Regulation FD Disclosure (Jun 30, 2026)

Labcorp Holdings Inc. (NYSE: LH) filed a Form 8-K on June 30, 2026 under Item 7.01 (Regulation FD Disclosure) to announce that it will release its second-quarter 2026 financial results before the market opens on Thursday, July 30, 2026. The company will host a webcast and conference call beginning at 9:00 a.m. ET that day to discuss the results. The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website. The filing itself contains no financial results, guidance, or performance figures. Its substance is the scheduling of the earnings release and call. A copy of the June 30, 2026 press release is furnished as Exhibit 99.1, which is the announcement of the earnings date and webcast details; a replay of the webcast will be available on the investor relations website about two hours after the live event and for one year. The press release describes Labcorp as a global laboratory services company with nearly 71,000 employees serving clients in approximately 100 countries, supporting more than 85% of new drugs and therapeutic products approved by the FDA in 2025, and performing more than 750 million tests for patients worldwide. For investors, the key takeaway is the timing of the Q2 2026 results and the opportunity to hear management commentary on the call.

Labcorp Holdings 8-K Report, Regulation FD Disclosure (May 27, 2026)

Labcorp Holdings Inc. (NYSE: LH) furnished a Current Report on Form 8-K under Item 7.01 (Regulation FD Disclosure) on May 27, 2026, announcing that it will present at the 2026 Jefferies Global Healthcare Conference in New York on Wednesday, June 3, from 12:15 pm to 12:45 pm ET. The presentation will be available via live webcast on the Labcorp Investor Relations website at ir.labcorp.com. The filing is informational in nature and contains no financial results, guidance, or other quantitative financial data. An archived recording of the session will be available approximately 24 hours after the session ends and can be accessed for 90 days following the event. The accompanying press release (Exhibit 99.1) is incorporated by reference and furnished under this Item. The press release also describes Labcorp as a global laboratory services company with nearly 71,000 employees serving clients in approximately 100 countries, supporting more than 85% of new drugs and therapeutic products approved by the FDA in 2025, and performing more than 750 million tests for patients worldwide. For investors, the filing is primarily a scheduling notice for management's conference appearance rather than a source of new financial information.

Labcorp Holdings 8-K Report, Shareholder Vote Results (May 26, 2026)

Labcorp Holdings Inc. filed this Current Report under Item 5.07 to disclose the results of its 2026 Annual Meeting of Shareholders. As of the March 26, 2026 record date, 82,187,046 shares of common stock were outstanding and entitled to vote, and holders of 76,382,627 shares were represented in person or by proxy, constituting a quorum. The vote results are described as final, as certified by the Inspector of Elections. Shareholders elected all eleven director nominees listed in the proxy statement filed April 10, 2026, each to a term expiring at the 2027 Annual Meeting. Support was generally strong, with most nominees receiving well over 65 million votes for. Garheng Kong, M.D., Ph.D. received the lowest support, with 50,153,535 votes for and 20,110,931 votes against. Several other directors received between roughly 2.7 million and 5.3 million votes against. Shareholders also approved, on an advisory basis, the compensation of the named executive officers, with 66,519,291 votes for and 3,735,777 votes against. Shareholders ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the year ending December 31, 2026, with 76,291,589 votes for and 53,650 votes against.

Labcorp Holdings Quarterly Report for Q1 Ended Mar 31, 2026

Labcorp Holdings Inc. (LH) reported revenues of $3,537.6 million for the three months ended March 31, 2026, up from $3,345.1 million a year earlier, and net earnings attributable to Labcorp Holdings Inc. of $277.8 million versus $212.8 million. Diluted EPS was $3.35 compared with $2.52. Operating income rose to $380.8 million from $326.0 million, and the company attributed the revenue increase to organic revenue growth of 3.1%, acquisitions net of divestitures of 1.4%, and favorable foreign currency translation of 1.3%. Diagnostics Laboratories (Dx) revenues were $2,762.1 million, up 5.0%, and Biopharma Laboratory Services (BLS) revenues were $780.6 million, up 8.2%. Cash flow improved markedly. Net cash provided by operating activities was $191.5 million versus $18.5 million in the prior-year quarter, which the company attributed primarily to higher cash earnings. Cash and cash equivalents rose to $981.1 million from $532.3 million at December 31, 2025. Long-term debt increased to $5,833.7 million from $5,084.6 million, driven by a new $750.0 million 2026 Term Loan entered on March 20, 2026, which the company anticipates using to repay maturing short-term debt. The company also repurchased 0.4 million shares for $98.0 million and paid $61.2 million in dividends during the quarter. The company stated it was in compliance with its debt covenants at March 31, 2026, and believes it has sufficient liquidity for the next 12 months. Pending matters include the Parkview Health System outreach laboratory asset acquisition, expected at up to $165.0 million and anticipated to close in 2026, and several legal matters, including a Texas Medicaid qui tam case and a Ravgen patent judgment under appeal, which the company says it will vigorously defend.

Labcorp Holdings 8-K Report, Financial Results (Apr 30, 2026)

Labcorp Holdings Inc. filed this Form 8-K on April 30, 2026 to furnish its press release (Exhibit 99.1) announcing first quarter 2026 results and raised full-year 2026 guidance. Revenue for the quarter was $3.54 billion versus $3.35 billion a year earlier, up 5.8%, with organic growth of 3.1%, acquisitions contributing 1.4% and foreign exchange 1.3%. Diluted EPS rose to $3.35 from $2.52, and Adjusted EPS rose 10.6% to $4.25 from $3.84. Adjusted operating income was $507.9 million, a 14.4% margin versus 14.0% a year earlier. Net earnings attributable to Labcorp Holdings Inc. were $277.8 million, compared with $212.8 million. Both segments grew. Diagnostics Laboratories revenue was $2.76 billion, up 5.0%, with an AOI margin of 16.6%. Biopharma Laboratory Services revenue was $780.6 million, up 8.2%, with Central Labs revenue growth of 11.3% and Early Development growth of 0.6%. Biopharma's TTM book-to-bill was 1.04 and backlog was $8.64 billion. Operating cash flow was $191.5 million and free cash flow was $70.5 million, compared with negative $107.5 million a year earlier. The company raised its 2026 guidance. Revenue is now expected at $14.65 billion to $14.80 billion, growth of 5.0% to 6.1%, and Adjusted EPS at $17.70 to $18.35, up 13 cents at the midpoint to $18.03. Free cash flow guidance was unchanged at $1.24 billion to $1.36 billion. Total debt rose to $6.33 billion at quarter end, which the company attributed to pre-funding of maturing debt, and cash was $981.1 million.

Labcorp Holdings 8-K Report, Regulation FD Disclosure (Apr 9, 2026)

Labcorp Holdings Inc. (NYSE: LH) filed a Current Report on Form 8-K on April 9, 2026, under Item 7.01 (Regulation FD Disclosure) to announce that its Board of Directors has declared a quarterly cash dividend of $0.72 per share of common stock. The dividend is payable on June 11, 2026, to stockholders of record as of the close of business on May 29, 2026. The filing is a routine capital return announcement with no financial results, guidance, or operational updates included in the 8-K itself. The accompanying press release, furnished as Exhibit 99.1 and incorporated by reference, carries the same dividend details and describes Labcorp as a global laboratory services provider with nearly 71,000 employees serving clients in approximately 100 countries. For investors, the key takeaways are the dividend amount, the record date, and the payment date. The filing does not disclose any other financial metrics, and the Exhibit 99.1 press release contains no additional financial data beyond the dividend announcement.

Labcorp Holdings 8-K Report, Regulation FD Disclosure (Mar 31, 2026)

Labcorp Holdings Inc. (NYSE: LH) filed this Current Report on Form 8-K on March 31, 2026 under Item 7.01 (Regulation FD Disclosure) to announce the timing of its first-quarter 2026 financial results. The company will release those results before the market opens on Thursday, April 30, 2026, and will host a conference call and webcast beginning at 9:00 a.m. ET that day to discuss them. The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website, and a replay of the webcast will be available there approximately two hours after the live event, for one year. The press release dated March 31, 2026 is furnished as Exhibit 99.1 and is incorporated by reference. The filing itself contains no financial results, guidance, or operating metrics. Its substance is administrative: it sets the date and format for the company's Q1 2026 earnings disclosure. The Exhibit 99.1 announcement also describes Labcorp as a global laboratory services provider with nearly 71,000 employees serving clients in approximately 100 countries, and notes it performed more than 750 million tests for patients around the world.

Labcorp Holdings 8-K Report, Material Agreement (Mar 20, 2026)

On March 20, 2026, Labcorp Holdings Inc. (the "Company"), as parent guarantor, and Laboratory Corporation of America Holdings ("LCAH"), as borrower, entered into a Term Loan Credit Agreement with Wells Fargo Bank, National Association, as administrative agent, and a syndicate of lenders. The agreement provides for a $750 million senior unsecured term loan scheduled to mature on March 20, 2028, which was fully funded on the Closing Date. The Term Loan bears interest at a floating rate, either a SOFR-based rate plus a 0.700% margin or a base rate plus a 0% margin. The Credit Agreement includes customary representations, warranties, and affirmative and negative covenants, including restrictions on liens, mergers and consolidations, and dispositions of substantially all assets, subject to exceptions. It also requires the Company to maintain a consolidated leverage ratio of not more than 4.0 to 1.0 as of each quarter-end. That ratio may be raised to 4.5 to 1.0 for four fiscal quarters following a material acquisition, a "Leverage Holiday," which LCAH may elect an unlimited number of times, though a further election requires the ratio to return to 4.0 to 1.0 or below for at least two fiscal quarters first. The filing also notes that some lenders and their affiliates have provided and may continue to provide commercial banking, investment banking, and other financial advisory services to the Company for customary fees. The full Credit Agreement is filed as Exhibit 10.1, with certain exhibits and schedules omitted under Item 601(a)(5) of Regulation S-K.

Labcorp Holdings Annual Report, Year Ended Dec 31, 2025

Labcorp Holdings Inc. (LH) reported 2025 revenues of $13,951.7 million, up 7.2% from $13,008.9 million in 2024, driven by organic revenue growth of 4.4%, acquisitions net of divestitures of 2.5%, and favorable foreign currency translation of 0.4%. Operating income rose to $1,384.7 million from $1,086.7 million, and net earnings attributable to Labcorp Holdings Inc. were $876.5 million, versus $746.0 million in 2024. Diluted EPS was $10.46, compared with $8.84 in 2024. Dx (Diagnostics Laboratories) generated $10,876.5 million in revenue with segment operating income of $1,779.9 million, while BLS (Biopharma Laboratory Services) generated $3,098.2 million with segment operating income of $498.5 million. Cash flow from operations was $1,640.5 million, compared with $1,585.8 million in 2024. Cash and cash equivalents fell to $532.3 million from $1,518.7 million, reflecting $1,194.0 million used for investing activities (including $582.0 million in acquisitions and $434.5 million in capital expenditures) and $1,457.0 million used for financing activities, which included $450.0 million in share repurchases and $240.7 million in dividends. Senior notes principal totaled $5.2 billion, and the company had $1.0 billion available under its revolving credit facility at year-end. The filing also highlights ongoing reimbursement pressure from PAMA, with rate reductions frozen for 2026 and capped at 15% per year for 2027 to 2029 under the Consolidated Appropriations Act. Management plans to raise capital expenditures to approximately 4.0% of revenues. Pending legal matters include the Ravgen patent judgment, which the company is appealing, and the AMCA data incident, for which the company has reached a term sheet to settle the class action.

Labcorp Holdings 8-K Report, Financial Results (Feb 17, 2026)

Labcorp Holdings Inc. furnished its fourth-quarter and full-year 2025 results and 2026 guidance under Item 2.02 of this Form 8-K, via Exhibit 99.1, a press release. Full-year 2025 revenue was $13.95 billion, up from $13.01 billion, and the filing states full-year revenue growth of 7.2%, with organic growth of 4.4%. Full-year diluted EPS was $10.46 versus $8.84, and adjusted EPS was $16.44 versus $14.57. Fourth-quarter revenue was $3.52 billion versus $3.33 billion, and fourth-quarter adjusted EPS was $4.07 versus $3.45. Fourth-quarter GAAP diluted EPS of $1.98 was lower than the adjusted figure, and fourth-quarter restructuring and other charges rose to $110.8 million from $11.4 million. Full-year free cash flow was $1.21 billion, compared with $1.10 billion in 2024. Fourth-quarter free cash flow fell to $490.3 million from $665.1 million, which the company attributed to working capital timing. The company ended the year with $532.3 million of cash and $5.58 billion of total debt. It invested $582.0 million in acquisitions during 2025, repurchased $450.0 million of stock, and paid $240.7 million in dividends. The board declared a quarterly dividend of $0.72 per share, payable March 12, 2026. For 2026, Labcorp guided to revenue of $14.61 billion to $14.79 billion (midpoint growth of 5.4%), adjusted EPS of $17.55 to $18.25 (midpoint growth of 8.9%), and free cash flow of $1.24 billion to $1.36 billion (midpoint growth of 7.8%). The filing also highlights a planned 500,000 square foot Central Laboratory facility in Indiana, with construction expected to begin later in 2026, and a backlog of $8.72 billion at year-end, up 9.2%.

Labcorp Holdings 8-K Report, Executive Changes (Feb 9, 2026)

Labcorp Holdings Inc. (NYSE: LH) filed a Form 8-K on February 9, 2026, to report the appointment of John H. Sampson, M.D., Ph.D., to its Board of Directors, effective February 9, 2026. The Board appointed Dr. Sampson on February 6, 2026, and assigned him to the Quality and Compliance Committee. He will receive compensation for Board service under the company's director compensation program, as described in its most recent proxy statement filed April 4, 2025. Dr. Sampson is vice chancellor for health affairs and dean of the University of Colorado Anschutz School of Medicine. Previously he held senior leadership roles at Duke University Health System, where he served as senior vice president and led the Duke Health Integrated Practice. He is a practicing neurosurgeon, a member of the National Academy of Medicine, and has authored nearly 300 peer-reviewed publications. The company says his expertise in oncology, neuroscience, women's health and personalized medicine aligns with its strategic focus areas. The filing is a governance announcement and does not disclose financial results, guidance, or transaction terms. The company issued a press release on February 9, 2026, announcing the appointment, which is filed as Exhibit 99.1.

Labcorp Holdings 8-K Report, Material Agreement (Jan 29, 2026)

Labcorp Holdings Inc. (LH) disclosed in this Form 8-K, filed January 29, 2026, that on January 28, 2026 it entered into a Second Amendment to its Receivables Purchase Agreement with Labcorp Receivables LLC, Laboratory Corporation of America Holdings, PNC Bank, National Association (as administrative agent), and the other parties thereto. The company acknowledged and agreed to the amendment. Under the RPA Amendment, the scheduled termination date was extended to January 26, 2029. A committed $125 million accordion facility was added, allowing Labcorp Receivables, at its option, to increase the facility limit from $700 million to up to $825 million at any time on or before May 29, 2026. The 0.10% SOFR adjustment previously added to capital accruing yield at daily 1M SOFR or term SOFR rate was removed. The filing also states that Labcorp Receivables is a separate legal entity with its own creditors, who will have access to its assets before those assets become available to the Company. Labcorp Receivables assets are therefore not available to pay creditors of the Company or its subsidiaries (other than Labcorp Receivables), although collections in excess of amounts needed to repay the Purchasers and other Labcorp Receivables creditors may be remitted to the Company. The full amendment is filed as Exhibit 10.1.

Labcorp Holdings 8-K Report, Regulation FD Disclosure (Jan 15, 2026)

Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, filed this Current Report under Item 7.01 (Regulation FD Disclosure) on January 15, 2026 to announce the timing of its fourth-quarter 2025 financial results. The company will release those results before the market opens on Tuesday, February 17, 2026, and will host a listen-only conference call and webcast beginning at 9 a.m. ET that day to discuss them. The filing is largely procedural and contains no financial results, guidance, or forward-looking figures. The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website, and a press release dated January 15, 2026 is furnished as Exhibit 99.1. A replay of the webcast will be available approximately two hours after the live event and until February 4, 2027. For investors, the key takeaway is the date and format of the upcoming earnings release and call. The 8-K itself does not disclose quarterly performance, so any assessment of Labcorp's fourth-quarter 2025 results must await the February 17, 2026 release.

Labcorp Holdings 8-K Report, Regulation FD Disclosure (Jan 14, 2026)

Labcorp Holdings Inc. (NYSE: LH) filed a Current Report on Form 8-K dated January 14, 2026, under Item 7.01 (Regulation FD Disclosure). The company announced that its Board of Directors has declared a quarterly cash dividend of $0.72 per share of common stock. The dividend is payable on March 12, 2026, to stockholders of record as of the close of business on February 27, 2026. The announcement is also furnished as Exhibit 99.1, a press release dated January 14, 2026, which is incorporated by reference into the filing. The filing is routine in nature and contains no financial results, guidance, or other operational disclosures. For investors, the key takeaways are the dividend amount and the record and payment dates.

Labcorp Holdings 8-K Report, Regulation FD Disclosure (Dec 30, 2025)

Labcorp Holdings Inc. (NYSE: LH) filed a Current Report on Form 8-K dated December 30, 2025, under Item 7.01 (Regulation FD Disclosure). The filing states that the company will participate in a fireside chat at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13 at 4:30 p.m. Pacific Time. The filing contains no financial results, guidance, or other financial metrics. A live audio webcast of the fireside chat will be available through the company's Investor Relations website at ir.Labcorp.com, and the webcast will be archived for replay. The accompanying press release, furnished as Exhibit 99.1, announces the participation and describes Labcorp as a global leader of laboratory services with nearly 70,000 employees serving clients in approximately 100 countries. For investors, this filing is an event notice rather than a source of new financial information. Its main value is in signaling management's scheduled public appearance at a major healthcare investor conference and providing access details for the webcast.

Labcorp Holdings 8-K Report, Executive Changes (Dec 15, 2025)

Labcorp Holdings Inc. filed a Form 8-K dated December 9, 2025 (filed December 15, 2025) under Item 5.02, reporting a leadership change. Mark Schroeder, Executive Vice President and President, Diagnostics Laboratories and Chief Operations Officer, notified the company on December 9, 2025 of his intention to retire, effective April 1, 2026. The filing is brief and contains no financial results, guidance, or other financial metrics. The only substantive disclosure is the planned departure of a senior operating executive who oversees the Diagnostics Laboratories segment and serves as Chief Operations Officer. The filing does not state a successor or replacement arrangements. For investors, the key takeaway is a scheduled executive transition roughly three and a half months after the notice date. Investors may want to monitor future filings or announcements for a successor appointment and any effect on operations at the Diagnostics Laboratories business.

Labcorp Holdings 8-K Report, Executive Changes (Dec 10, 2025)

Labcorp Holdings Inc. (LH) filed a Form 8-K on December 10, 2025 to report that Dr. D. Gary Gilliland notified the Board of Directors on December 5, 2025 of his decision to retire from the Board, effective December 31, 2025. The filing is disclosed under Item 5.02 (Departure of Directors or Certain Officers) and Item 7.01 (Regulation FD Disclosure). The company issued a press release on December 10, 2025, announcing the retirement, attached as Exhibit 99.1. The release states that Dr. Gilliland became a director in 2014, served on the Audit Committee and the Quality and Compliance Committee, and has been President and Director Emeritus of the Fred Hutchinson Cancer Research Center since January 2020. Chairman and CEO Adam Schechter credited him with extensive knowledge of oncology and gene therapy and cited more than 10 years of service. Dr. Garheng Kong, lead independent director and chair of the Nominating and Corporate Governance Committee, praised his contributions to strengthening the company. For investors, this is a routine board transition with no financial results, guidance, or operational changes disclosed in the filing. The filing does not state a successor or any replacement arrangement.

Labcorp Holdings 8-K Report, Executive Changes (Nov 24, 2025)

Labcorp Holdings Inc. (LH) filed this Form 8-K on November 24, 2025 to report the appointment of Victor Bulto to its Board of Directors. The Board appointed Mr. Bulto on November 20, 2025, with his board service effective December 1, 2025. He will receive compensation consistent with the Company's director compensation program, as described in its most recent proxy statement filed April 4, 2025. Mr. Bulto is President of Novartis U.S. and a member of the Novartis Executive Committee, roles he has held since April 2022. The filing describes more than two decades of senior Novartis experience across major therapeutic areas and several geographies, including President of U.S. Pharmaceuticals, Head of U.S. Alcon Pharmaceuticals, and Head of the Neuroscience Franchise for Region Europe. The accompanying press release states that he oversees a U.S. business of more than $20 billion across oncology, immunology, neuroscience, and cardiovascular-renal-metabolic therapeutic areas. The filing is a governance update with no financial results, guidance, or transaction disclosed. Chairman and CEO Adam Schechter is quoted as saying Bulto's experience will support the Company's strategic priorities, particularly around science, technology, and customer value.

Labcorp Holdings Quarterly Report for Q3 Ended Sep 30, 2025

Labcorp Holdings Inc. reported third-quarter 2025 revenues of $3,563.5 million, up from $3,282.0 million in the prior-year quarter, and net earnings attributable to Labcorp Holdings Inc. of $261.1 million, compared with $169.3 million a year earlier. Diluted earnings per share were $3.12, versus $2.00. For the nine months ended September 30, 2025, revenues were $10,435.9 million and diluted EPS was $8.48. The filing attributes the quarterly revenue increase of 8.6% to organic revenue growth of 6.2%, acquisitions net of divestitures of 1.7%, and favorable foreign currency translation of 0.7%. Operating income rose to $396.6 million from $254.1 million, aided by lower general corporate and unallocated expenses, which fell to $109.9 million from $172.5 million. Cash generation was steady, with operating cash flow of $1,026.3 million for the nine months versus $808.6 million a year earlier. Cash and cash equivalents declined to $598.1 million from $1,518.7 million at December 31, 2024, as the company repaid $1,000.0 million of senior notes, paid $225.0 million for share repurchases and $181.4 million in dividends, and spent $324.0 million on acquisitions and $179.9 million on equity affiliate investments. Total debt on the balance sheet was roughly $5.58 billion, and the company reported $1,000.0 million of available borrowings under its revolver. The filing also points to pending transactions: an agreement to acquire select outreach assets from Community Health Systems for approximately $195.0 million, expected to close in the fourth quarter of 2025, and an agreement to acquire select clinical laboratory assets from Empire City Laboratories for up to $250.0 million, expected to close in the first quarter of 2026. Management disclosed the One Big Beautiful Bill Act, which could reduce insurance coverage and diagnostic testing utilization, but stated it does not expect a material impact on results of operations in future periods.

Labcorp Holdings 8-K Report, Financial Results (Oct 28, 2025)

Labcorp Holdings Inc. furnished an 8-K on October 28, 2025 attaching Exhibit 99.1, a press release announcing its 2025 third-quarter results and updated full-year guidance. Third-quarter revenue was $3.56 billion versus $3.28 billion a year earlier, up 8.6%, with organic growth of 6.2% and acquisitions contributing 1.7%. Diluted EPS was $3.12 versus $2.00, and adjusted EPS was $4.18 versus $3.50, up 19.4%. Operating income rose to $396.6 million (11.1% of revenue) from $254.1 million, and adjusted operating income reached $513.3 million (14.4% of revenue). Free cash flow was $280.5 million versus $161.5 million, and the company repurchased $25.0 million of stock during the quarter. Cash and cash equivalents ended the quarter at $598 million and total debt at $5.58 billion. The Diagnostics Laboratories segment grew revenue 8.5% to $2.77 billion, while Biopharma Laboratory Services grew 8.3% to $799.1 million. The filing notes the company is beginning to divest or restructure approximately $50 million of annual Early Development revenue. For full-year 2025, Labcorp narrowed its enterprise revenue growth guidance to 7.4% to 8.0%, with the midpoint lowered 40 bps due to currency and acquisition timing. Adjusted EPS guidance is $16.15 to $16.50, with the midpoint raised by $0.05, and free cash flow guidance is $1.17 billion to $1.29 billion, with the midpoint raised by $25 million.

Labcorp Holdings 8-K Report, Regulation FD Disclosure (Oct 8, 2025)

Labcorp Holdings Inc. (NYSE: LH) filed a Current Report on Form 8-K on October 8, 2025, under Item 7.01 (Regulation FD Disclosure) to announce that its Board of Directors declared a quarterly cash dividend of $0.72 per share of common stock. The dividend is payable on December 11, 2025, to stockholders of record as of the close of business on November 26, 2025. The filing is a routine capital-return announcement with no financial results, guidance, or material transactions disclosed. The accompanying press release (Exhibit 99.1), furnished rather than filed, repeats the dividend terms and includes the company's standard boilerplate describing its business: a global provider of laboratory services with nearly 70,000 employees serving clients in approximately 100 countries. For investors, the key takeaway is the declared dividend amount and its timing. The filing contains no information on the company's operating performance, financial position, or strategic developments.

Labcorp Holdings 8-K Report, Regulation FD Disclosure (Sep 25, 2025)

Labcorp Holdings Inc. (NYSE: LH) furnished a Current Report on Form 8-K under Item 7.01 (Regulation FD Disclosure) on September 25, 2025, announcing the timing of its third-quarter 2025 financial results. The company will release those results before the market opens on Tuesday, October 28, 2025, and will host a conference call and webcast beginning at 9 a.m. ET that day to discuss them. The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website. A press release dated September 25, 2025, announcing the earnings date is furnished as Exhibit 99.1 and incorporated by reference. The exhibit describes the call as listen-only, with a replay available about two hours after the live event and accessible until October 15, 2026. The filing itself contains no financial results, guidance, or operating metrics. Its main value for investors is scheduling: it identifies the date and time of the company's Q3 2025 earnings release and call. The exhibit also describes Labcorp as a global laboratory services company with nearly 70,000 employees serving clients in approximately 100 countries.

Labcorp Holdings 8-K Report, Regulation FD Disclosure (Aug 28, 2025)

Labcorp Holdings Inc. (NYSE: LH) filed a Form 8-K on August 28, 2025 under Item 7.01 (Regulation FD Disclosure) to announce that members of its executive management team will take part in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9, 2025, at 7:45 am ET. The filing furnishes a press release dated August 27, 2025 as Exhibit 99.1, which is incorporated by reference. The filing contains no financial results, guidance, or material financial figures. A live audio webcast of the fireside chat will be available through the company's Investor Relations website at ir.Labcorp.com, with a replay archived afterward. Investors seeking management commentary on the business can use this as a scheduled opportunity to hear from executives, though the filing itself does not indicate what topics will be discussed. The press release describes Labcorp as a global laboratory services company with nearly 70,000 employees serving clients in approximately 100 countries. It states that the company supported more than 75% of new drugs and therapeutic products approved by the FDA in 2024 and performs more than 700 million tests annually.

Labcorp Holdings Quarterly Report for Q2 Ended Jun 30, 2025

Labcorp Holdings Inc. (LH) reported second-quarter 2025 revenues of $3.53 billion, up from $3.22 billion a year earlier, with organic revenue growth of 5.4% and acquisitions contributing 3.5%. Operating income rose to $394.5 million from $294.8 million, and net earnings attributable to Labcorp Holdings Inc. were $237.9 million, or $2.84 diluted EPS, versus $205.3 million, or $2.43, in the prior-year quarter. Diagnostics Laboratories (Dx) generated about 78% of revenues and Biopharma Laboratory Services (BLS) about 22%. Dx segment operating income was $482.8 million, and BLS segment operating income was $123.3 million. For the six months ended June 30, 2025, revenues were $6.87 billion, up 7.4%, and net cash provided by operating activities was $639.1 million, compared with $531.3 million a year earlier. The company repaid $1.0 billion of 3.60% senior notes due 2025 and used $200.0 million to repurchase common stock. Cash and cash equivalents fell to $647.3 million from $1.52 billion at December 31, 2024, while long-term debt was $5.08 billion. Other, net expense of $32.7 million in the quarter reflected investment losses of $31.3 million, and the company also entered an equity method investment in SYNLAB. The filing also discloses pending acquisitions of select assets of BioReference Health's oncology lab business (up to $225.0 million) and select outreach assets of Community Health Systems (approximately $195.0 million), expected to close in the second half of 2025 and fourth quarter of 2025, respectively. Legal matters disclosed include a Ravgen patent judgment under appeal and a Texas Medicaid qui tam action. The company reported that it was in compliance with its debt covenants and expects to remain so for the next 12 months.

Labcorp Holdings 8-K Report, Financial Results (Jul 24, 2025)

Labcorp Holdings Inc. reported second-quarter 2025 results in a Form 8-K furnishing Exhibit 99.1, a press release announcing 2025 Second Quarter Results. Revenue rose to $3.53 billion from $3.22 billion, a 9.5% increase, with organic growth of 5.4% and acquisitions contributing 3.5%. Diluted EPS was $2.84 versus $2.43, and adjusted EPS was $4.35 versus $3.94, up 10.4%. Operating income margin was 11.2% versus 9.2%, and adjusted operating margin was 15.1% versus 14.9%. The company raised its 2025 guidance. Enterprise revenue growth is now expected at 7.5% to 8.6%, with the midpoint raised by 70 basis points. Adjusted EPS guidance is narrowed to $16.05 to $16.50, with the midpoint raised by $0.23, and free cash flow guidance is $1.13 billion to $1.28 billion, with the midpoint raised by $25 million. The company attributes the raise primarily to currency and the underlying strength of its businesses. Diagnostics Laboratories revenue grew 8.9% to $2.75 billion, and Biopharma Laboratory Services revenue grew 11.0% to $784.8 million, with organic growth of 7.8%. Biopharma backlog reached $8.71 billion, up 10.0% year over year. At quarter end, cash and cash equivalents were $0.65 billion and total debt was $5.58 billion. During the quarter, the company repurchased $200.0 million of stock and declared a quarterly dividend of $0.72 per share.

Labcorp Holdings 8-K Report, Regulation FD Disclosure (Jul 10, 2025)

Labcorp Holdings Inc. (NYSE: LH) filed a Current Report on Form 8-K dated July 10, 2025, under Item 7.01 (Regulation FD Disclosure) to announce that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend is payable on September 11, 2025, to stockholders of record as of the close of business on August 28, 2025. The announcement is furnished as Exhibit 99.1, a press release dated July 10, 2025, which is incorporated by reference. The press release describes Labcorp as a global leader of innovative and comprehensive laboratory services, with nearly 70,000 employees serving clients in approximately 100 countries. It also states that the company provided support for 75% of the new drugs and therapeutic products approved by the FDA in 2024 and performed more than 700 million tests annually. For investors, the filing is a routine capital-return notice: a quarterly cash dividend with a defined record date and payment date. It does not contain financial results, guidance, or other operating updates.

Labcorp Holdings 8-K Report, Material Agreement (Jun 27, 2025)

Labcorp Holdings Inc. (LH) disclosed on June 27, 2025 that it, as parent guarantor, and Laboratory Corporation of America Holdings (LCAH), as borrower, entered into a Fourth Amended and Restated Credit Agreement with Bank of America, N.A., as administrative agent, and the other lenders party thereto. The agreement provides a $1,000,000,000 senior unsecured revolving credit facility, including a $100,000,000 swingline subfacility and a $150,000,000 sublimit for letters of credit, scheduled to mature on June 27, 2030. It amends and restates the Third Amended and Restated Credit Agreement dated April 30, 2021, which provided a $1,000,000,000 facility scheduled to mature on April 30, 2026. As of the closing date, there were no outstanding borrowings under the Credit Facility. The Credit Facility carries floating-rate pricing tied to LCAH's long-term debt ratings: SOFR-based borrowings at a margin of 0.805% to 1.300%, or base-rate borrowings at a margin of 0% to 0.300%. A facility fee of 0.070% to 0.200% is payable quarterly on total commitments regardless of usage. The agreement allows an increase of up to $500,000,000, subject to conditions including obtaining additional lender commitments. The agreement includes customary representations, affirmative and negative covenants, and events of default, and requires a consolidated leverage ratio of not more than 4.0 to 1.0 as of each quarter-end. The ratio may rise to 4.5 to 1.0 for four fiscal quarters following a material acquisition (a "Leverage Holiday"), which may be elected an unlimited number of times, subject to a requirement that the ratio return to 4.0 to 1.0 for at least two fiscal quarters before another election. Upon an event of default, outstanding loans may be accelerated. The Company also disclosed that some lenders and their affiliates provide commercial banking, investment banking and advisory services to the Company in the ordinary course for customary fees.

Labcorp Holdings 8-K Report, Regulation FD Disclosure (Jun 26, 2025)

Labcorp Holdings Inc. (NYSE: LH) furnished this Form 8-K under Item 7.01 (Regulation FD Disclosure) to announce that it will release its financial results for the second quarter of 2025 before the market opens on Thursday, July 24, 2025. The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results, and the earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website. The filing is a scheduling announcement and contains no financial results, guidance, or operating metrics. The accompanying press release (Exhibit 99.1), dated June 26, 2025, describes the call logistics: the webcast will be live and listen-only, participants are advised to join 10 minutes before the start, and a replay will be available approximately two hours after the live event through July 11, 2026. The press release also describes Labcorp as a global laboratory services company with nearly 70,000 employees serving clients in approximately 100 countries, and states that it provided support for more than 75% of the new drugs and therapeutic products approved in 2024 by the FDA and performs more than 700 million tests annually.

Labcorp Holdings 8-K Report, Executive Changes (May 20, 2025)

Labcorp Holdings Inc. filed this Form 8-K to report the results of its 2025 Annual Meeting of Shareholders, held May 15, 2025. Shareholders approved the Labcorp Holdings Inc. 2025 Omnibus Incentive Plan and the 2025 Employee Stock Purchase Plan (2025 ESPP), with full descriptions set out in the company's April 4, 2025 proxy statement. The copies of both plans are filed as Exhibits 10.1 and 10.2. At the meeting, 76,049,607 of the 83,668,573 shares outstanding and entitled to vote as of the March 20, 2025 record date were represented, constituting a quorum. All ten director nominees were elected to terms expiring at the 2026 Annual Meeting. Shareholders also approved the named executive officer compensation on an advisory basis, with 64,147,316 votes for and 5,634,146 against, and ratified Deloitte & Touche LLP as the independent registered public accounting firm for 2025, with 75,696,303 votes for and 297,066 against. For investors, the filing's main substance is the approval of new equity compensation vehicles and the confirmation of board and auditor appointments. Vote tallies show that several director nominees received notably more votes against than others, while the say-on-pay and plan proposals passed by clear margins. The filing does not discuss financial results or operating developments.

Labcorp Holdings 8-K Report, Regulation FD Disclosure (May 8, 2025)

Labcorp Holdings Inc. (NYSE: LH) filed a Form 8-K dated May 8, 2025, under Item 7.01 (Regulation FD Disclosure) to announce that its Annual Meeting of Shareholders will be webcast live on May 15, 2025 at 9:00 a.m. ET. Investors can view the webcast on the Labcorp Investor Relations website, and an archived replay will be available for one year. The filing is administrative in nature and does not contain financial results, guidance, or other material financial information. It furnishes a press release (Exhibit 99.1) that restates the webcast announcement and includes the company's standard boilerplate description, which states the company has nearly 70,000 employees, serves clients in approximately 100 countries, supported more than 75% of new drugs and therapeutic products approved by the FDA in 2024, and performs more than 700 million tests annually. For investors, the main takeaway is the scheduling of the annual shareholder meeting, which is a routine governance event. The filing does not report any votes, proposals, or changes in corporate governance.

Labcorp Holdings 8-K Report, Financial Results (Apr 29, 2025)

Labcorp Holdings Inc. reported first quarter 2025 results on April 29, 2025, under Item 2.02 of this Form 8-K, furnishing a press release as Exhibit 99.1. Revenue rose to $3.35 billion from $3.18 billion, with diluted EPS of $2.52 versus $2.69 and adjusted EPS of $3.84 versus $3.68. Organic revenue grew 2.1%, acquisitions added 3.7%, and foreign exchange reduced growth by 0.5%. Operating income was $326.0 million compared with $321.3 million, while adjusted operating income rose to $469.0 million from $452.8 million, though adjusted operating margin declined 20 basis points to 14.0%, which the company attributed to Invitae. The company reaffirmed its 2025 revenue guidance of 6.7% to 8.0% and free cash flow guidance of $1.10 billion to $1.25 billion, and raised the midpoint of its adjusted EPS range by $0.05 to a range of $15.70 to $16.40. First-quarter free cash flow was negative $107.5 million, compared with negative $163.6 million a year earlier, as operating cash flow improved to $18.5 million from negative $29.8 million, primarily due to timing of working capital. Year-end cash and cash equivalents were $0.37 billion and total debt was $5.57 billion. The release also highlighted partnership and acquisition activity, including a strategic collaboration with Inspira Health, an agreement to acquire select assets of BioReference Health's oncology testing businesses, and completion of the North Mississippi Health Services outreach laboratory asset acquisition. The Diagnostics Laboratories segment grew revenue 6.0% to $2.63 billion, while Biopharma Laboratory Services grew 1.5% to $721.3 million with backlog of $8.18 billion. A quarterly dividend of $0.72 per share was declared, payable June 11, 2025.

Labcorp Holdings Quarterly Report for Q1 Ended Mar 31, 2025

Labcorp Holdings Inc. (LH) reported first-quarter 2025 revenues of $3,345.1 million, up from $3,176.6 million a year earlier, with the filing attributing the increase to acquisitions, net of divestitures, of 3.7% and organic revenue growth of 2.1%, partly offset by unfavorable foreign currency translation of 0.5%. Operating income rose to $326.0 million from $321.3 million, while net earnings attributable to Labcorp Holdings Inc. declined to $212.8 million from $228.0 million, and diluted EPS was $2.52 versus $2.69. Interest expense increased to $56.0 million from $46.9 million, reflecting higher average debt outstanding, and Other, net fell to a $(1.0) million expense from $20.0 million, primarily due to lower transition services fees charged to Fortrea. Liquidity was reshaped during the quarter. Cash and cash equivalents fell to $369.4 million from $1,518.7 million at year-end 2024 after the company repaid $1,000.0 million of 3.60% senior notes due 2025 and invested $157.0 million in equity affiliates, including the SYNLAB minority interest. Operating cash flow improved to $18.5 million from a $(29.8) million outflow, which the filing attributes primarily to timing of working capital requirements. Long-term debt rose to $5,568.7 million, partly due to an increase in the accounts receivable facility balance to $525.0 million, and the company amended its AR facility to allow borrowings up to $700.0 million. The company had $1,000.0 million of undrawn revolving credit facility capacity at quarter end. The filing also details ongoing legal matters, including the Ravgen patent case (with a jury damages award of $272.0 million from 2022 and subsequent orders), the AMCA data security multidistrict litigation, and a Texas Medicaid qui tam action. The company states it will vigorously defend these matters and that it does not believe they will have a material adverse effect on its financial statements, though the Ravgen matter's outcome is disclosed as uncertain pending appeal.

Labcorp Holdings 8-K Report, Regulation FD Disclosure (Apr 10, 2025)

Labcorp Holdings Inc. (NYSE: LH) filed a Form 8-K on April 10, 2025 under Item 7.01 (Regulation FD Disclosure) to announce that its Board of Directors has declared a quarterly cash dividend of $0.72 per share of common stock. The dividend is payable on June 11, 2025, to stockholders of record as of the close of business on May 29, 2025. The announcement is furnished rather than filed, and the accompanying Exhibit 99.1 is a press release dated April 10, 2025, headlined "Labcorp Declares Quarterly Dividend." That release repeats the dividend amount, payment date and record date, and includes the company's boilerplate description: a global laboratory services provider with nearly 70,000 employees serving clients in approximately 100 countries. The filing contains no financial results, guidance, or operating metrics beyond that boilerplate. For investors, the filing's significance is limited to the declared dividend and its timing, which is a routine capital return announcement.

Labcorp Holdings 8-K Report, Regulation FD Disclosure (Mar 31, 2025)

Labcorp Holdings Inc. (NYSE: LH) filed this Current Report on Form 8-K under Item 7.01 (Regulation FD Disclosure) on March 31, 2025, to announce the timing of its first-quarter 2025 financial results. The company will release those results before the market opens on Tuesday, April 29, 2025, and will host a conference call and webcast beginning at 9 a.m. ET that day to discuss them. The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website. The filing contains no financial results, guidance, or other quantitative performance data. Its substantive content is logistical: the release date, the conference call timing, and access details. The webcast is listen-only, participants may register via a link to receive dial-in numbers and a unique PIN, and a replay will be available approximately two hours after the live event until April 16, 2026. The company describes itself as a global leader in laboratory services, citing nearly 70,000 employees, service to clients in approximately 100 countries, support for more than 75% of new drugs and therapeutic products approved by the FDA in 2024, and more than 700 million tests performed annually. The filing's Exhibit 99.1 is a press release dated March 31, 2025 announcing the earnings date and call details.

Labcorp Holdings Annual Report, Year Ended Dec 31, 2024

Labcorp Holdings Inc. (LH) reported 2024 revenues of $13,008.9 million, up 7.0% from $12,161.6 million in 2023. Organic revenue grew 3.9% (Base Business up 4.9%, partly offset by a 1.0% decrease in COVID-19 Testing), acquisitions net of divestitures contributed 2.8%, and favorable foreign currency translation added 0.2%. Operating income rose to $1,086.7 million from $725.6 million, aided by the absence of the prior year's $349.0 million goodwill and asset impairment charge. Diluted EPS from continuing operations was $8.84, versus $4.33 in 2023. Net earnings attributable to Labcorp Holdings were $746.0 million, compared with $418.0 million in 2023. Operating cash flow from continuing operations was $1,585.8 million. Diagnostics Laboratories (Dx) generated $10,144.3 million of revenue and $1,606.3 million of segment operating income, a 15.8% operating margin. Biopharma Laboratory Services (BLS) generated $2,922.6 million of revenue and $458.9 million of segment operating income, a 15.7% operating margin. The company invested $839.0 million in acquisitions during 2024, including Invitae and BioReference Health, and repurchased $250.1 million of stock. It paid $243.1 million in dividends and ended the year with $1,518.7 million in cash. Total senior notes principal was about $6.2 billion, and the company issued $2.0 billion of new senior notes in September 2024. The filing highlights regulatory and reimbursement risk. The 2026 PAMA reduction of $100.0 million in Medicare reimbursement is expected, unless implementation is further delayed or changed. FDA's final rule on laboratory-developed tests (LDTs), with first compliance obligations starting May 6, 2025, is under legal challenge. The company also disclosed ongoing litigation, including the Ravgen patent verdict, in which the court awarded damages and ongoing royalties, and the AMCA data incident litigation.

Labcorp Holdings 8-K Report, Financial Results (Feb 6, 2025)

Labcorp Holdings Inc. filed this Form 8-K on February 6, 2025 to furnish its Exhibit 99.1 press release announcing fourth-quarter and full-year 2024 results and providing 2025 guidance. For full-year 2024, revenue from continuing operations was $13.01 billion versus $12.16 billion in 2023, with diluted EPS from continuing operations of $8.84 (versus $4.33) and adjusted EPS of $14.57 (versus $13.56). Fourth-quarter revenue was $3.33 billion versus $3.03 billion, and fourth-quarter diluted EPS was $1.70 versus $(1.95), which reflected goodwill and asset impairments of $333.8 million in the prior-year quarter. Free cash flow from continuing operations was $1.10 billion for the full year, versus $748.7 million in 2023. Management highlighted that the company announced 10 transactions in 2024, including the acquisition of select assets from Lab Works and select outreach laboratory services from Ballad Health, and a subsequent collaboration with Inspira Health. Organic revenue growth was 5.4% in the fourth quarter and 3.9% for the year as reported in the release, and acquisitions contributed 4.0% in the quarter. Year-end cash was $1.52 billion and total debt was $6.33 billion, which the company attributed to pre-funding of maturing debt. For 2025, Labcorp guided to revenue of $13.88 billion to $14.05 billion, adjusted EPS of $15.60 to $16.40, and free cash flow of $1.10 billion to $1.25 billion. The company also declared a quarterly cash dividend of $0.72 per share, payable March 12, 2025. The release notes that the Clinical Development and Commercialization Services business was spun off as Fortrea Holdings Inc., and that adjusted measures are non-GAAP.

Labcorp Holdings 8-K Report, Material Agreement (Jan 31, 2025)

On January 31, 2025, Labcorp Holdings Inc. entered into the First Amendment to its Receivables Purchase Agreement, among Labcorp Receivables LLC, Laboratory Corporation of America Holdings, PNC Bank, National Association as administrative agent, and the other parties, with the Company acknowledging and agreeing to the amendment. The filing reports under Items 1.01 and 2.03 that the facility limit increased from $300 million to $700 million, a material expansion of the receivables financing arrangement. The amendment also changed the purchaser group. The Toronto-Dominion Bank joined as a committed purchaser with a scheduled commitment termination date of January 30, 2026. MUFG Bank Ltd. and certain of its related conduit purchasers joined as purchasers, and their loans or investments may accrue interest at the CP Rate plus an applicable margin. The scheduled commitment termination date of August 23, 2027 and the interest terms for all other committed purchasers were not changed. The filing states that Labcorp Receivables is a separate legal entity with its own creditors, and its assets are not available to pay creditors of the Company or its subsidiaries other than Labcorp Receivables. Collections in excess of amounts needed to repay purchasers and other Labcorp Receivables creditors may be remitted to the Company. The full terms are in Exhibit 10.1, which is incorporated by reference.